The new production technology enables real-time monitoring of the quality of 3D cell products, which are living cells in three-dimensional structures. This type of monitoring, which has been historically challenging for researchers, in turn supports more stable manufacturing of quality cell products. In this collaboration, Cyfuse used its proprietary Bio 3D Printing technology to manufacture 3D cell constructs and PHC used in-line monitoring technology in its LiCellGrowTM(*3) cell expansion system under development to track metabolic activity in the cell constructs. By combining these technologies, the companies successfully improved the quality and stability of 3D cell products during cultivation.
To build on this development, PHC and Cyfuse aim to develop a next-generation type of cell expansion system called a circulation cell culture system that incorporates the new production technology. This new device will seek to identify critical process parameters in the 3D cell product manufacturing process, monitor cell conditions in real time during production, and optimize the manufacturing process based on the state of the cells. The companies hope to contribute to improving the quality and stability of 3D cell products like those Cyfuse develops.
The details of this development will be presented at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, scheduled to be held at Pacifico Yokohama in Yokohama, Japan from March 20 to March 22, 2025. The companies will showcase their research findings through poster presentations, focusing on the ongoing development of the circulation cell culture system, as well as the quality evaluation of Cyfuse's 3D cell products cultured using this system.
PHC and Cyfuse will continue to advance their joint research efforts to accelerate the practical application of various production technologies. The companies also aim to expand the value chain within the growing field of regenerative and cell therapy. They will seek to promote research and development, technological innovation, and the creation of new products, including Cyfuse’s regenerative medicine products. Furthermore, by strengthening corporate collaboration including strategic partnerships, PHC and Cyfuse are committed to driving growth and advancement in this field through this partnership.
About the Biomedical Division of PHC Corporation:
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO2 incubators and ultra-low temperature freezers.
About PHC Holdings Corporation (PHC Group):
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
About Cyfuse Biomedical K.K.:
Cyfuse Biomedical K.K. (Securities Code: 4892, TSE Growth) is a regenerative medicine startup founded in 2010. Using its proprietary bio 3D printing technology, which creates three-dimensional tissues solely from cells without artificial scaffolds, the company develops innovative regenerative medicine products and sells Bio 3D printers, Regenova® and S-PIKE®.
